search
Back to results

PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children

Primary Purpose

Constipation

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
polyethyleneglycol3350
Sponsored by
Braintree Laboratories
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Constipation

Eligibility Criteria

4 Years - 16 Years (Child)All Sexes

Inclusion Criteria: Male or female outpatients between the ages of 4 to 16 years. Adolescent female patients must not be pregnant or lactating. constipated according to ROME I definition Two or fewer bowel movements during the initial observation week. Absence of a stool impaction Bowel movement after receiving enema Are otherwise in good health, as judged by a physical examination. Parent or guardian is mentally competent to sign an instrument of informed consent Exclusion Criteria: Patients with heme positive stool at baseline exam. Patients with fecal impaction at baseline, or after the observation period, as indicated by physical exam Patients with known or suspected perforation or obstruction other than fecal impaction. Patients who are breastfeeding, pregnant or intend to become pregnant during the study. Female patients of childbearing potential who refuse a pregnancy test. Patients with a known history of organic cause for their constipation. Patients with congenital malformations that produce constipation (Hirschsprung's disease, imperforate anus, children with cerebral palsy or other neurologic abnormalities, or systemic diseases). History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy. Use of concomitant medications that cause constipation Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures. Patients with known allergy to polyethyleneglycol or polyethyleneglycol containing medications. Patients with clinically significant elevations of TSH or abnormal plasma electrolytes. Patients who, within the past 30 days have participated in an investigational clinical study

Sites / Locations

Outcomes

Primary Outcome Measures

Greater than 2 bowel movements per week

Secondary Outcome Measures

Analysis of individual ROME I criteria
Safety (adverse event and laboratory testing)

Full Information

First Posted
September 7, 2005
Last Updated
February 6, 2013
Sponsor
Braintree Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT00153114
Brief Title
PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children
Official Title
PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
January 2003 (undefined)
Primary Completion Date
September 2004 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Braintree Laboratories

4. Oversight

5. Study Description

Brief Summary
Assess the safety and efficacy of polyethyleneglycol3350 laxative as compared to placebo therapy in pediatric patients with a history of constipation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
100 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
polyethyleneglycol3350
Primary Outcome Measure Information:
Title
Greater than 2 bowel movements per week
Secondary Outcome Measure Information:
Title
Analysis of individual ROME I criteria
Title
Safety (adverse event and laboratory testing)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
16 Years
Eligibility Criteria
Inclusion Criteria: Male or female outpatients between the ages of 4 to 16 years. Adolescent female patients must not be pregnant or lactating. constipated according to ROME I definition Two or fewer bowel movements during the initial observation week. Absence of a stool impaction Bowel movement after receiving enema Are otherwise in good health, as judged by a physical examination. Parent or guardian is mentally competent to sign an instrument of informed consent Exclusion Criteria: Patients with heme positive stool at baseline exam. Patients with fecal impaction at baseline, or after the observation period, as indicated by physical exam Patients with known or suspected perforation or obstruction other than fecal impaction. Patients who are breastfeeding, pregnant or intend to become pregnant during the study. Female patients of childbearing potential who refuse a pregnancy test. Patients with a known history of organic cause for their constipation. Patients with congenital malformations that produce constipation (Hirschsprung's disease, imperforate anus, children with cerebral palsy or other neurologic abnormalities, or systemic diseases). History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy. Use of concomitant medications that cause constipation Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures. Patients with known allergy to polyethyleneglycol or polyethyleneglycol containing medications. Patients with clinically significant elevations of TSH or abnormal plasma electrolytes. Patients who, within the past 30 days have participated in an investigational clinical study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samuel Nurko, MD
Organizational Affiliation
Boston Children's Hospital
Official's Role
Principal Investigator
Facility Information:
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07962
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States

12. IPD Sharing Statement

Learn more about this trial

PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children

We'll reach out to this number within 24 hrs